It means absolutely nothing BV. This finance nonsense is regularly dredged up. They’ve cash in the bank, burn rates are down, Dx income is up. They’ve cash until the end of the year and they’ll get any cash they need via a deal or raising. End of finance FUD, back to the nonsense about Fiona.
It’s the age old ink problem Timster. First Alan’s pot ran dry just as he was about to sign transformation deals with Boris, this time the auditors are going to run out and won’t be able to sign off the accounts. We’ve had a good run. Best of luck everyone.
I noticed that codejunkie. It's not a coincidence. Bless em. 20p placing on the way it seems. Like last time that dogsh.t gravel teeth released some clickbait. Given the 1500 posts a day you'd think he'd be writing an article about HE1 and that the helium they've found is actually sulphur. Meanwhile, suppose we just wait until we're suspended because a random website says we've no cash 🤷🏻♂️
I'd suggest it all needs to be written - Qs in advance and answers in a blog post. No face to face so there's no extra info for the ego driven crowd to laud over everyone. If it's absolutely necessary then get Paul Hill involved but it definitely needs questions submitted in advance as Alan's last attempt to answer on the spot was an embarrassing garbled mess.
‘The two-weekly dosing study will aim to take patients with a more defined set of cancers than was the case in the three-weekly study and these may also have different treatment histories. This is designed to help further inform the choice of indications for the Phase 2 study. If it is possible to enrol patients earlier in their treatment journey then that is a decision for the treating oncologist.’
Suppose I'll just keep posting it. No guesswork required on this one
‘The two-weekly dosing study will aim to take patients with a more defined set of cancers than was the case in the three-weekly study and these may also have different treatment histories. This is designed to help further inform the choice of indications for the Phase 2 study. If it is possible to enrol patients earlier in their treatment journey then that is a decision for the treating oncologist.’
‘The two-weekly dosing study will aim to take patients with a more defined set of cancers than was the case in the three-weekly study and these may also have different treatment histories. This is designed to help further inform the choice of indications for the Phase 2 study. If it is possible to enrol patients earlier in their treatment journey then that is a decision for the treating oncologist.’
That's why you don't reply on their disruptive threads - they subsequently report them themselves to get them taken down after they've humiliated themselves. Just report and ignore or bin. We know who the trolls are and new incarnations aren't difficult to spot.
Ah Myles, the voice of 'the majority' who peddles some really stupid ideas - yes, let's flog Dx at a loss and retain the debt. I'd rather keep him clear.
Rather than setting up more coffee and cake sessions, just collate them and then publish any responses so that all investors receive the same information. Also, the example given is terrible. They've had an affimer sales pitch on their website for years describing superiority over antibodies - it's done nothing commercially. Creating another pamphlet for pre|Cision over ADCs does nothing other than give cosy feelings. I'd prefer not to waste their time answering pointless questions and get out there selling it to long term investors and BP rather than pandering PIs. They've hired someone to do just that. They answered a LOT of questions following the last InvestorMeet for a change. Just request a quarterly InvestorMeet rather than half yearly and be more organised with the questions at that point.
I’m not a subscriber to the Twatter school of commercial stupidity. Latest brilliant idea is flogging Dx at a 10m loss. Brilliant idea. Lose a profitable revenue stream and keep a chunk of debt. All whilst speaking on behalf of ‘the majority’. Idiots.
AHS, gotta wonder why you care about someone else’s opinion of a ‘business’ you’re not invested in. Perhaps next time someone mentions £20 just chuckle and move on. Another day, another account, more sulphuric stench. How many accounts are in THE ROOM?
AHS, no one (apart from the ramping twatterati) is saying this should be valued at £20 today. There is potential that it could be at some point based on either licencing / deals which lead to sufficient funding to get ava6k to market or an overnight leap based on BP making a takeover approach. It might be £20, it might be £8, it might be £50. The potential of the platform and the IP is the investment case. It's an early stage biotech that's now in the clinic, it's currently priced at the value the market believes it's worth, no opinion needed. As things progress that'll change. It's a long term investment and the rainbow chasers looking for overnight big gains would be better off in a casino. Another day, another collection of pointless FUD and on for 100 posts again. There's nothing to talk about right now.